X4 Pharmaceuticals is currently conducting a Phase 3 clinical trial to evaluate an investigational treatment (Mavorixafor) for chronic neutropenic disorders, including congenital, autoimmune, and idiopathic forms., and they're seeking participants who could benefit from this research while helping advance care for the entire neutropenia community.
Is this study right for you?
The study is currently looking for participants who:
• Are 12 years or older
• Have been diagnosed with chronic neutropenia for at least 6 months
• Experience recurrent or serious infections
How to learn more:
To learn more, schedule a brief conversation with the study’s nurse coordinator. They can help you understand the details of the trial and if participation may be right for you and your family.
If you qualify and choose to participate, you will:
• Access an investigational treatment: Receive Mavorixafor, a potential new therapy not yet available to the general public.
• Receive specialized care: Be closely monitored by a team of neutropenia specialists throughout the study.
• No-cost participation: Receive all study-related investigational treatments and medical procedures at no cost.
• Travel & expense support: X4 Pharmaceuticals will provide reimbursement for approved travel, lodging, and meals if needed.
• Make an impact: Contribute to advancing medical knowledge that could benefit the entire neutropenia community.
Your participation is voluntary, and you can decide to stop at any time.
